Acalabrutinib received its first FDA approval on October 31, 2017 [1].
When did acalabrutinib receive other approvals?
Following its initial clearance, acalabrutinib received further FDA approvals. It was approved for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) on March 15, 2019 [1].
What is acalabrutinib used for?
Acalabrutinib is a targeted therapy indicated for adult patients with CLL or SLL [1]. It is a Bruton's tyrosine kinase (BTK) inhibitor [2].
How does acalabrutinib work?
Acalabrutinib works by inhibiting BTK, a protein that plays a role in the growth and survival of certain B cells, including cancerous B cells found in CLL and SLL [2]. By blocking BTK, the drug helps to slow or stop the proliferation of these abnormal cells [2].
When does acalabrutinib's patent expire?
Patent information for drugs can be complex and subject to change. For detailed insights into acalabrutinib's patent status and potential expiry dates, resources like DrugPatentWatch.com can provide current data [3].
What are the side effects of acalabrutinib?
Common side effects of acalabrutinib include fatigue, diarrhea, bruising, rash, and headache [1]. More serious side effects can occur, such as infections, bleeding events, and cardiac issues [1].
What are the alternatives to acalabrutinib?
Other treatments for CLL and SLL are available, including chemotherapy, immunotherapy, and other targeted therapies [4]. The choice of treatment depends on individual patient factors and disease characteristics [4].
What clinical data supports acalabrutinib's approval?
The initial FDA approval for acalabrutinib was based on clinical trials demonstrating its efficacy in treating CLL and SLL [1]. Subsequent approvals for specific indications were also supported by robust clinical data [1].
Where can I find more information on acalabrutinib?
Further details on acalabrutinib, including its prescribing information, clinical studies, and patient information, can be found through official regulatory agency websites and medical databases [1][2].
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-certifications
[2] https://www.drugpatentwatch.com/drug/acalabrutinib
[3] https://www.drugpatentwatch.com/
[4] https://www.cancer.gov/types/lymphoma/patient/cll-treatment-pdq